NewAmsterdam Pharma Co N.V. — Form 8-K
Filed July 24, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
NewAmsterdam Pharma and Menarini Group received a positive Committee for Medicinal Products for Human Use (CHMP) opinion recommending European marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (obicetrapib 10 mg plus ezetimibe 10 mg fixed-dose combination) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM trial data showing 40% LDL-C reduction with monotherapy and 50% with combination versus placebo. European Commission final decision expected in H2 2026; NewAmsterdam is entitled to tiered double-digit to mid-twenties percentage royalties on net sales and up to €833 million in milestone payments.
Why this rating
Major regulatory milestone for lead asset in $1.3B company; EU approval potential unlocks significant revenue stream and de-risks business trajectory. Material but not transformational—depends on final EC approval and PREVAIL cardiovascular outcomes data.
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.